Anthracyclines News and Research

RSS

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Treatments for childhood cancer have resulted in a current overall cure rate of over 70 percent. However, long-term survivors of childhood cancer are at a higher risk of developing a secondary cancer than the general population.

20 Feb 2007

Study indicates heart damage from some cancer drugs worsens over the years

It is well documented that some anti-cancer drugs can damage the heart, but a long-term follow-up of children and young adults who had doxorubicin[1] treatment for bone tumours suggests that the damage gets progressively worse as the years go on.

19 Jul 2006

HERA trial continues to demonstrate significant patient benefits from Herceptin

New 23-month follow-up data from HERA, one of the largest breast cancer trials ever carried out, show that Herceptin (trastuzumab) following standard chemotherapy significantly reduced the risk of death by 34% for women with early-stage HER2-positive breast cancer.

5 Jun 2006

Genes variations raise risk of heart disease after treatment for childhood cancer

Gene variations may raise the risk that survivors of childhood cancer will suffer congestive heart failure as a complication of drugs they received during cancer treatment.

5 Jun 2006

Gene amplification could guide treatment for high-risk breast cancer

A new study shows that breast cancer patients with an "amplification," or greater number of copies, of the TOP2A gene are 45% more likely than women who do not have this amplification to benefit from a longer course of anthracycline-based adjuvant chemotherapy.

11 May 2006

Great news for breast cancer patients

In encouraging new study results researchers say that modern treatments have significantly boosted the 15-year survival rate for breast cancer, and even better news is that they have also found that drug and hormonal therapies effectively cure many women, rather than simply delaying the recurrence of disease.

12 May 2005

Combination chemotherapy shows small survival benefit in advanced stomach cancer

Patients with advanced stomach cancer have the best chance of prolonging their survival with a combination of chemotherapies instead of just one, according to a new review of previous studies.

19 Apr 2005

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study

9 Jun 2004

Gemcitabine may help breast cancer patients with advanced disease live longer

6 Jun 2004

First patient dosed with Tesmilifene in pivotal breast cancer study

YM BioSciences Inc., the cancer drug development company, today announced that the first patient has been dosed in its 700 patient Phase III registration trial.

31 Mar 2004